Emergent BioSolutions | EBS - Umsatzkosten

Aktienkurs
8.81
Täglich Wechseln
0.19 2.20%
Monatlich
10.13%
Jährlich
94.05%
Q2 Prognose
8.43




Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Akebia Therapeutics USD 10.34M 441K 2025-12
ALKERMES USD 46.21M 5.38M 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amarin USD 26.05M 1.41M 2025-12
ANI Pharmaceuticals USD 122.88M 6.86M 2025-12
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Coherus Biosciences USD 4.04M 324K 2025-12
Emergent BioSolutions USD 381.2M 226.1M 2023-06
Exelixis USD 26.48M 7.91M 2025-12
Glaxosmithkline GBP 3.47B 461.37M 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Lexicon Pharmaceuticals USD 201K 191K 2025-12
Lonza CHF 2.28B 189M 2025-06
Merck USD 3.32B 531M 2025-12
Moderna USD 452M 245M 2025-12
Myriad Genetics USD 63M 1.1M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Pacira USD 54.62M 6.02M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Sanofi EUR 4.29B 421M 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
United Therapeutics USD 474.7M 373.8M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Xoma 116K 112.7K 2024-06